Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
Phase 1
Completed
- Conditions
- Acute Myelogenous LeukemiaLeukemia
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00943943
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00942734
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
Phase 2
Terminated
- Conditions
- LeukemiaPediatric Cancer
- Interventions
- Procedure: Infusion of NK cells
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00941928
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
Phase 1
Completed
- Conditions
- Advanced Cancers
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT00941499
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Enhanced Smoking Cessation for University Students
Not Applicable
Completed
- Conditions
- Current Every Day SmokerCigarette Smoker
- Interventions
- Other: Survey Administration
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00941395
- Locations
- 🇺🇸
Texas A&M, College Station, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT00940342
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sirolimus and Cetuximab in Advanced Malignancies
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 165
- Registration Number
- NCT00940381
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
TTP607 in Refractory Solid Malignancies
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00939172
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00939159
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Phase 2
Completed
- Conditions
- Testicular Cancer
- Interventions
- Procedure: Stem Cell Transplant
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00936936
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States